HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

HENGRUI PHARMA

66.400

+0.4000.61%

Volume:1.54M

Turnover:102.12M

Market Cap:440.70B

PE:49.76

High:67.000

Open:64.900

Low:64.550

Close:66.000

52wk High:95.200

52wk Low:52.500

Shares:6.64B

HK Float Shares:258.00M

Volume Ratio:3.45

T/O Rate:0.60%

Dividend:- -

Dividend Rate:- -

EPS(LYR):1.334

ROE:14.31%

ROA:8.42%

PB:6.36

PE(LYR):49.76

PS:12.32

Loading ...

Overview Company News Filings

Earning Preview: HENGRUI PHARMA this quarter’s revenue is expected to increase by 0%, and institutional views are cautiously optimistic

Hengrui Pharma Secures Nod to Market Likang Kepan Fumarate Drug

MT Newswires Live

Hengrui Pharma's Subsidiary Gets Nod for Clinical Trial of Atopic Dermatitis Drug Combination

MT Newswires Live

Hong Kong Market Announcements: Ant Group's Acquisition of Bright Smart Receives Approval, Trading Resumes March 17

Jiangsu Hengrui Pharmaceuticals Gets China Clinical Trial Nod for Pancreatic Cancer Injection

MT Newswires Live

Hengrui Pharma's HRS-5965 Capsule Drug Application Accepted for Review

Hengrui Pharma Receives NMPA Clearance for Clinical Trials of SHR-1819 and SHR-1905 Injections in Atopic Dermatitis

Hengrui Pharmaceutical Gets China Nod for Type 2 Diabetes Injectable

MT Newswires Live

Jiangsu Hengrui Pharmaceutical Gets China Nod for Blood Autoimmune Disease Drug

MT Newswires Live

Wellington Management Increases Stake in Hengrui Pharma by 49,600 Shares

Hengrui Medicine Gets China Nod for New Indication of Hetrombopag Olamine Tablets

MT Newswires Live

Hengrui Pharma (01276) Secures NMPA Approval to Add New Indication for Hetrombopag Olamine Tablets

Bulletin Express

Wellington Management Increases Stake in Hengrui Pharma by 49,600 Shares at HK$66.13 Each

Hengrui Pharma Receives Regulatory Clearance for Clinical Trial of Irinotecan Liposome Injection

Hengrui Pharma's Innovative Drug Hetrombopag Olamine Tablets Gain Additional Indication

Hengrui Pharmaceuticals Gets Nod to Trial SHR-9803 for Injection

MT Newswires Live

HENGRUI PHARMA (01276) Sets 25 March 2026 Board Meeting to Approve FY 2025 Results and Final Dividend

Bulletin Express

Hengrui Medicine Gets Nod for Chronic Kidney Disease Drug Trial

MT Newswires Live

China Stocks Rise on Hopes for End to Middle East Crisis; CATL Jumps 5% on Higher Profit

MT Newswires Live

Jiangsu Hengrui Pharmaceuticals Gets China Nod for Two Anti-Tumor Injectables

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/01276/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"01276","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","market":"HK","secType":"STK","nameCN":"HENGRUI PHARMA","latestPrice":66.4,"timestamp":1774837114220,"preClose":66,"halted":0,"volume":1542000,"delay":0,"changeRate":0.0060606060606061465,"floatShares":258000000,"shares":6637000000,"eps":1.3342887125952494,"marketStatus":"Trading","change":0.4,"latestTime":"03-30 10:18:51","open":64.9,"high":67,"low":64.55,"amount":102120365,"amplitude":0.037121,"askPrice":66.45,"askSize":8600,"bidPrice":66.35,"bidSize":2600,"shortable":3,"etf":0,"ttmEps":1.3342887125952494,"tradingStatus":2,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1774843200000},"marketStatusCode":2,"adr":0,"listingDate":1747929600000,"exchange":"SEHK","adjPreClose":66,"openAndCloseTimeList":[[1774834200000,1774843200000],[1774846800000,1774857600000]],"volumeRatio":3.447941,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600276","market":"SH","secType":"STK","nameCN":"Jiangsu Hengrui Pharmaceuticals Co.,Ltd.","latestPrice":55.39,"timestamp":1774837130000,"preClose":55.18,"halted":0,"volume":30569600,"delay":0,"premium":"+6.02"}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"01276\",,,,,undefined,":{"symbol":"01276","floatShares":258000000,"roa":"8.42%","roe":"14.31%","lyrEps":1.334289,"volumeRatio":3.447941,"shares":6637000000,"dividePrice":0,"high":67,"amplitude":0.037121,"preClose":66,"low":64.55,"week52Low":52.5,"pbRate":"6.36","psRate":"12.32","week52High":95.2,"institutionHeld":0,"latestPrice":66.4,"committee":-0.535714,"eps":1.3342887125952494,"divideRate":0,"volume":1542000,"delay":0,"ttmEps":1.3342887125952494,"open":64.9,"prevYearClose":71.25,"prevWeekClose":66,"prevMonthClose":66.5,"prevQuarterClose":71.25,"fiveDayClose":61.8,"twentyDayClose":64,"sixtyDayClose":71.3},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/01276\",params:#limit:5,,,undefined,":[{"date":"2026-03-26","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774488600000,"name":null,"time":"","dateTimestamp":1774454400000,"actualEps":null},{"date":"2025-10-28","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1761615000000,"name":null,"time":"","dateTimestamp":1761580800000,"actualEps":null},{"date":"2025-08-21","symbol":"01276","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1755739800000,"name":null,"time":"","dateTimestamp":1755705600000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"01276\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"01276\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.2222,"buy":0.6667,"hold":0.1111,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":9,"updateTime":1772208000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/01276\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"01276","date":"2026-03-27","current":49.331142,"percent":0.014218,"low":44.415436,"twenty":51.400677,"median":54.94883,"eighty":60.443129,"high":65.582363,"avg":55.568695,"sd":4.750737,"marketCap":414588875872.42},"quantilePoints":[{"date":"2025-05-23","current":52.570963,"twenty":52.783176,"median":53.101495,"eighty":53.419815,"marketCap":390693388207.53},{"date":"2025-05-30","current":53.015805,"twenty":51.822085,"median":52.540895,"eighty":52.926837,"marketCap":395731540422.24},{"date":"2025-06-06","current":52.120101,"twenty":52.130014,"median":52.555929,"eighty":53.075252,"marketCap":390038198012.59},{"date":"2025-06-13","current":52.209491,"twenty":52.177631,"median":52.691227,"eighty":53.357137,"marketCap":390861633032.23},{"date":"2025-06-20","current":50.172412,"twenty":51.591196,"median":52.469796,"eighty":53.075252,"marketCap":374874997562.85},{"date":"2025-06-27","current":50.314776,"twenty":50.363569,"median":52.169666,"eighty":53.013533,"marketCap":376991477472.78},{"date":"2025-07-04","current":51.666141,"twenty":50.343584,"median":52.120101,"eighty":53.004446,"marketCap":387134991658.26},{"date":"2025-07-11","current":55.507007,"twenty":50.44351,"median":52.13337,"eighty":53.090114,"marketCap":415495681161.23},{"date":"2025-07-18","current":57.272274,"twenty":50.582121,"median":52.209491,"eighty":54.057606,"marketCap":428373566715.29},{"date":"2025-07-25","current":54.897923,"twenty":50.594414,"median":52.555929,"eighty":55.711415,"marketCap":412107620053.2},{"date":"2025-08-01","current":59.731878,"twenty":50.855059,"median":52.994419,"eighty":55.972407,"marketCap":445624526286.47},{"date":"2025-08-08","current":59.478715,"twenty":51.107295,"median":53.05296,"eighty":56.541585,"marketCap":444845815775.64},{"date":"2025-08-15","current":61.917611,"twenty":51.356483,"median":53.519848,"eighty":59.478715,"marketCap":462392609292.46},{"date":"2025-08-22","current":58.782188,"twenty":51.569512,"median":54.477764,"eighty":60.15932,"marketCap":470428104569.66},{"date":"2025-08-29","current":59.85298,"twenty":51.666141,"median":55.691374,"eighty":59.937003,"marketCap":481284287403.35},{"date":"2025-09-05","current":65.582363,"twenty":51.677932,"median":55.770266,"eighty":60.732448,"marketCap":526832269752.24},{"date":"2025-09-12","current":62.481332,"twenty":51.8337,"median":55.972407,"eighty":61.285609,"marketCap":502824785657.99},{"date":"2025-09-19","current":63.179889,"twenty":52.120101,"median":56.254853,"eighty":61.852995,"marketCap":508085671393.42},{"date":"2025-09-26","current":63.528382,"twenty":52.146639,"median":56.965096,"eighty":62.270337,"marketCap":509562668601.01},{"date":"2025-10-03","current":64.989073,"twenty":52.165061,"median":57.272274,"eighty":62.504861,"marketCap":522523002865.02},{"date":"2025-10-10","current":61.782766,"twenty":52.193561,"median":59.039802,"eighty":62.657943,"marketCap":496019912951.91},{"date":"2025-10-17","current":58.903713,"twenty":52.323014,"median":59.170669,"eighty":62.619084,"marketCap":472537436949.31},{"date":"2025-10-24","current":59.187086,"twenty":52.484015,"median":59.039802,"eighty":62.52839,"marketCap":474983377696.11},{"date":"2025-10-31","current":57.072441,"twenty":52.552922,"median":59.021138,"eighty":62.417499,"marketCap":465758305542.93},{"date":"2025-11-07","current":54.713071,"twenty":52.619069,"median":58.881843,"eighty":62.304573,"marketCap":446224987036.64},{"date":"2025-11-14","current":55.883072,"twenty":52.812504,"median":58.231971,"eighty":62.27542,"marketCap":457058673340.29},{"date":"2025-11-21","current":52.805265,"twenty":52.880927,"median":57.030538,"eighty":62.209511,"marketCap":431684582485.14},{"date":"2025-11-28","current":55.237621,"twenty":52.99843,"median":56.630614,"eighty":62.069705,"marketCap":453209419829.34},{"date":"2025-12-05","current":54.841023,"twenty":53.00899,"median":56.437545,"eighty":61.965159,"marketCap":450729029423.46},{"date":"2025-12-12","current":56.212257,"twenty":53.045529,"median":56.385682,"eighty":61.891765,"marketCap":462853512587.19},{"date":"2025-12-19","current":54.083493,"twenty":53.045529,"median":56.227363,"eighty":61.831221,"marketCap":446374731108.34},{"date":"2025-12-24","current":54.414957,"twenty":53.090114,"median":56.103073,"eighty":61.798561,"marketCap":450509359276.9},{"date":"2026-01-02","current":53.078544,"twenty":53.065996,"median":55.972407,"eighty":61.785925,"marketCap":441174507319.22},{"date":"2026-01-09","current":56.743223,"twenty":53.0878,"median":56.0944,"eighty":61.695241,"marketCap":472808676524.34},{"date":"2026-01-16","current":55.187351,"twenty":53.304215,"median":56.103073,"eighty":61.405393,"marketCap":461338821289.95},{"date":"2026-01-23","current":52.546341,"twenty":53.0878,"median":56.076447,"eighty":61.296167,"marketCap":438839874056.97},{"date":"2026-01-30","current":51.677141,"twenty":52.994149,"median":55.908509,"eighty":61.278475,"marketCap":433553740508.2},{"date":"2026-02-06","current":50.918226,"twenty":52.680723,"median":55.839154,"eighty":61.101743,"marketCap":428270226283.58},{"date":"2026-02-13","current":51.771686,"twenty":52.512455,"median":55.711415,"eighty":60.890064,"marketCap":437949787160.49},{"date":"2026-02-20","current":51.752043,"twenty":52.351169,"median":55.691374,"eighty":60.824953,"marketCap":437153052005.04},{"date":"2026-02-27","current":50.215456,"twenty":52.151244,"median":55.507566,"eighty":60.720339,"marketCap":428825318404.97},{"date":"2026-03-06","current":49.335298,"twenty":51.80347,"median":55.280584,"eighty":60.654676,"marketCap":417912584744.19},{"date":"2026-03-13","current":48.90444,"twenty":51.75217,"median":55.201025,"eighty":60.572606,"marketCap":416170839186.33},{"date":"2026-03-20","current":48.948437,"twenty":51.671435,"median":55.086674,"eighty":60.515374,"marketCap":414967977646.95},{"date":"2026-03-27","current":47.483832,"twenty":51.400677,"median":54.94883,"eighty":60.443129,"marketCap":414588875872.42}],"updateTime":1774796024095},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"01276\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1176414932","title":"Earning Preview: HENGRUI PHARMA this quarter’s revenue is expected to increase by 0%, and institutional views are cautiously optimistic","url":"https://stock-news.laohu8.com/highlight/detail?id=1176414932","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176414932?lang=en_us&edition=fundamental","pubTime":"2026-03-19 11:06","pubTimestamp":1773889595,"startTime":"0","endTime":"0","summary":"Earning Preview: HENGRUI PHARMA this quarter’s revenue is expected to increase by 0%, and institutional views are cautiously optimistic Abstract HENGRUI PHARMA will report its quarterly results on...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Earning Preview: HENGRUI PHARMA this quarter’s revenue is expected to increase by 0%, and institutional views are cautiously optimistic","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"gpt_icon":0},{"id":"2620114824","title":"Hengrui Pharma Secures Nod to Market Likang Kepan Fumarate Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2620114824","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620114824?lang=en_us&edition=fundamental","pubTime":"2026-03-17 10:25","pubTimestamp":1773714303,"startTime":"0","endTime":"0","summary":"China's National Medical Products Administration accepted Jiangsu Hengrui Pharmaceuticals'  marketing application for Likang Kepan fumarate , according to a Shanghai bourse filing on Tuesday.The drug was developed as a treatment for patients with paroxysmal nocturnal hemoglobinuria who remain anemic after previous treatment with C5 complement inhibitors.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01276","LU2543165471.USD","BK1191","LU0359202008.SGD","LU0359201885.HKD","LU0359201612.USD","LU1023057109.AUD"],"gpt_icon":0},{"id":"2620113484","title":"Hengrui Pharma's Subsidiary Gets Nod for Clinical Trial of Atopic Dermatitis Drug Combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2620113484","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620113484?lang=en_us&edition=fundamental","pubTime":"2026-03-17 10:12","pubTimestamp":1773713548,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals'  subsidiary, Guangdong Hengrui Medicine, received approval from China's National Medical Products Administration for the clinical trial of the drug combination of SHR-1819 injection and SHR-1905 injection, according to a Shanghai bourse filing on Tuesday.The drug combination will be tested as a treatment for atopic dermatitis.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2543165471.USD","LU0359201612.USD","01276","BK1191","LU0359202008.SGD","LU1023057109.AUD","LU0359201885.HKD"],"gpt_icon":0},{"id":"1192730058","title":"Hong Kong Market Announcements: Ant Group's Acquisition of Bright Smart Receives Approval, Trading Resumes March 17","url":"https://stock-news.laohu8.com/highlight/detail?id=1192730058","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1192730058?lang=en_us&edition=fundamental","pubTime":"2026-03-17 09:18","pubTimestamp":1773710304,"startTime":"0","endTime":"0","summary":"Major Corporate Developments: Hengrui Pharma (01276) announced that its SHR-1819 injection and SHR-1905 injection have received drug clinical trial approval notices. Henlius (02696) disclosed that...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"86c6cd7c917d7913316e328a31a00c76","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276","06688","HK0000320223.HKD","LU0359201612.USD","02696","LU0359202008.SGD","BK1191","HK0000165453.HKD","LU1023057109.AUD","VXUS","LU2543165471.USD","BK1521","02565","HK0000306701.USD","BK1606","BK1515","HK0000320264.USD","BK4588","LU0359201885.HKD","BK1197","01428","BK4585","HK0000306685.HKD","BK1147","00874","BK1161"],"gpt_icon":1},{"id":"2619456972","title":"Jiangsu Hengrui Pharmaceuticals Gets China Clinical Trial Nod for Pancreatic Cancer Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2619456972","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619456972?lang=en_us&edition=fundamental","pubTime":"2026-03-16 17:28","pubTimestamp":1773653337,"startTime":"0","endTime":"0","summary":"China's drug regulator approved clinical trials for the Irinotecan Hydrochloride Liposome Injection II made by Jiangsu Hengrui Pharmaceuticals  subsidiary Shanghai Hengrui, according to a Saturday filing with the Shanghai bourse.The drug is indicated for pancreatic cancer patients, the filing said.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0359201885.HKD","LU1023057109.AUD","01276","LU0359201612.USD","BK1191","LU2543165471.USD","LU0359202008.SGD"],"gpt_icon":0},{"id":"1148667061","title":"Hengrui Pharma's HRS-5965 Capsule Drug Application Accepted for Review","url":"https://stock-news.laohu8.com/highlight/detail?id=1148667061","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1148667061?lang=en_us&edition=fundamental","pubTime":"2026-03-16 17:28","pubTimestamp":1773653307,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (600276.SH) announced that its subsidiary, Chengdu Shengdi Pharmaceutical Co., Ltd., recently received a notice of acceptance from the National Medical...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828474.EUR","BK0028","BK0183","LU2097828714.EUR","LU2580892789.USD","LU0405327148.USD","BK0239","LU1023057109.AUD","LU1781817850.SGD","LU2097828557.USD","LU1064131003.USD","LU0359201612.USD","LU1969619763.USD","LU2097828805.USD","LU2148510915.USD","LU2580892862.HKD","LU1328615791.USD","LU1997244956.HKD","LU2097828631.EUR","01276","LU1997245094.SGD","BK1191","LU1064130708.USD","BK0060","LU1580142542.USD","LU2488822045.USD","LU1146622755.USD","LU2328871848.SGD","LU2543165471.USD","BK0196","LU1997245177.USD","LU1655091616.SGD","LU2495084118.USD","LU0359201885.HKD","BK0188","LU0405327494.USD","LU1820825898.SGD","BK0012","LU1255011170.USD","LU2289578879.USD","LU0359202008.SGD","600276"],"gpt_icon":0},{"id":"1161771503","title":"Hengrui Pharma Receives NMPA Clearance for Clinical Trials of SHR-1819 and SHR-1905 Injections in Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=1161771503","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161771503?lang=en_us&edition=fundamental","pubTime":"2026-03-16 17:22","pubTimestamp":1773652935,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (600276.SH) announced that its subsidiary, Guangdong Hengrui Pharmaceuticals Co., Ltd., has received a drug clinical trial approval notice from the National...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1969619763.USD","LU2148510915.USD","LU2289578879.USD","LU2097828474.EUR","LU2097828631.EUR","LU1820825898.SGD","BK0188","LU2097828805.USD","LU1328615791.USD","LU2097828557.USD","LU2495084118.USD","01276","BK0028","BK0196","BK0239","LU2543165471.USD","BK0060","LU2580892789.USD","LU0405327494.USD","LU1781817850.SGD","LU2097828714.EUR","LU2488822045.USD","LU0359201612.USD","LU0359201885.HKD","600276","LU1064131003.USD","LU2328871848.SGD","LU1655091616.SGD","LU1997244956.HKD","BK0012","LU0359202008.SGD","LU1580142542.USD","BK1191","LU1023057109.AUD","LU1146622755.USD","LU2580892862.HKD","LU1997245094.SGD","LU0405327148.USD","LU1064130708.USD","LU1255011170.USD","BK0183","LU1997245177.USD"],"gpt_icon":0},{"id":"2619455730","title":"Hengrui Pharmaceutical Gets China Nod for Type 2 Diabetes Injectable","url":"https://stock-news.laohu8.com/highlight/detail?id=2619455730","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619455730?lang=en_us&edition=fundamental","pubTime":"2026-03-16 17:12","pubTimestamp":1773652324,"startTime":"0","endTime":"0","summary":"China's drug regulator approved Jiangsu Hengrui Pharmaceutical's  injection for type 2 diabetes patients, according to a Saturday filing with the Shanghai bourse.The noliglutide injection helps control blood sugar in patients with poor glycemic control, combined with other drugs, the filing said.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01276","LU1023057109.AUD","LU0359202008.SGD","LU0359201612.USD","LU2543165471.USD","BK1191","LU0359201885.HKD"],"gpt_icon":0},{"id":"2619745532","title":"Jiangsu Hengrui Pharmaceutical Gets China Nod for Blood Autoimmune Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2619745532","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619745532?lang=en_us&edition=fundamental","pubTime":"2026-03-16 16:54","pubTimestamp":1773651245,"startTime":"0","endTime":"0","summary":"China's drug regulator approved a new indication for Jiangsu Hengrui Pharmaceutical's  hetrombopag ethanolamine tablets, according to a Saturday filing with the Shanghai bourse.The product is indicated for patients with chronic primary immune thrombocytopenic purpura, an acquired autoimmune disorder that mistakenly destroys platelets.Hengrui's new drug is also indicated for severe aplastic anemia patients who are not responsive to immunosuppressive therapy.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0359201885.HKD","LU0359201612.USD","01276","LU0359202008.SGD","BK1191","LU1023057109.AUD","LU2543165471.USD"],"gpt_icon":0},{"id":"1167236501","title":"Wellington Management Increases Stake in Hengrui Pharma by 49,600 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1167236501","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167236501?lang=en_us&edition=fundamental","pubTime":"2026-03-15 15:30","pubTimestamp":1773559824,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, on March 11, Wellington Management Group LLP purchased an additional 49,600 shares of Hengrui Pharma (01276). The transaction was...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0405327148.USD","01276","LU1781817850.SGD","BK0239","LU1580142542.USD","LU2097828474.EUR","BK0060","LU1820825898.SGD","LU2097828805.USD","LU0405327494.USD","BK0188","BK0196","LU1997245094.SGD","LU2580892862.HKD","LU2097828714.EUR","LU1328615791.USD","LU2289578879.USD","BK0012","LU2543165471.USD","LU1064131003.USD","LU1969619763.USD","LU1655091616.SGD","600276","LU0359202008.SGD","LU1023057109.AUD","LU2097828557.USD","BK0183","LU1146622755.USD","LU1997245177.USD","BK1191","LU0359201612.USD","LU2495084118.USD","LU1997244956.HKD","LU0359201885.HKD","LU2580892789.USD","LU2488822045.USD","LU1064130708.USD","LU1255011170.USD","LU2097828631.EUR","LU2148510915.USD","BK0028","LU2328871848.SGD"],"gpt_icon":0},{"id":"2619192865","title":"Hengrui Medicine Gets China Nod for New Indication of Hetrombopag Olamine Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2619192865","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619192865?lang=en_us&edition=fundamental","pubTime":"2026-03-13 20:14","pubTimestamp":1773404094,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine  obtained approval for Hetrombopag Olamine Tablets for adding a new indication from China's National Medical Products Administration, according to a Friday Hong Kong bourse filing.The approved indication is for use of the product in combination with immunosuppressive therapy for patients aged 15 years and older with treatment-naive severe aplastic anemia .","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0359201612.USD","SAA","LU0359201885.HKD","LU0359202008.SGD","BK1191","01276","LU2543165471.USD","LU1023057109.AUD"],"gpt_icon":0},{"id":"1150989700","title":"Hengrui Pharma (01276) Secures NMPA Approval to Add New Indication for Hetrombopag Olamine Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=1150989700","media":"Bulletin Express","labels":["policyRegulatory","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1150989700?lang=en_us&edition=fundamental","pubTime":"2026-03-13 19:42","pubTimestamp":1773402169,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (“Hengrui Pharma,” 01276.HK) announced that China’s National Medical Products Administration has cleared a new indication for the company’s self-developed...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"gpt_icon":0},{"id":"1156037404","title":"Wellington Management Increases Stake in Hengrui Pharma by 49,600 Shares at HK$66.13 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=1156037404","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156037404?lang=en_us&edition=fundamental","pubTime":"2026-03-13 19:40","pubTimestamp":1773402018,"startTime":"0","endTime":"0","summary":"According to the latest data from the Hong Kong Stock Exchange, Wellington Management Group LLP purchased an additional 49,600 shares of Hengrui Pharma (01276) on March 11. The transaction was...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0405327148.USD","LU2488822045.USD","600276","LU1969619763.USD","LU0359202008.SGD","LU1064130708.USD","01276","LU2097828714.EUR","LU1064131003.USD","LU1023057109.AUD","LU1997245177.USD","LU2580892862.HKD","LU2097828631.EUR","LU2289578879.USD","BK0012","BK0060","LU1820825898.SGD","LU2097828474.EUR","BK0239","LU1997244956.HKD","BK0196","LU2543165471.USD","LU2580892789.USD","LU0405327494.USD","LU2495084118.USD","LU2097828557.USD","BK1191","LU1580142542.USD","LU1146622755.USD","LU1255011170.USD","BK0028","LU1328615791.USD","LU2328871848.SGD","LU1781817850.SGD","BK0183","LU2097828805.USD","LU1655091616.SGD","LU1997245094.SGD","LU0359201885.HKD","LU2148510915.USD","LU0359201612.USD","BK0188"],"gpt_icon":0},{"id":"1176433773","title":"Hengrui Pharma Receives Regulatory Clearance for Clinical Trial of Irinotecan Liposome Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1176433773","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1176433773?lang=en_us&edition=fundamental","pubTime":"2026-03-13 17:54","pubTimestamp":1773395668,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (600276.SH) has announced that its subsidiary, Shanghai Hengrui Pharmaceutical Co., Ltd., recently obtained a drug clinical trial approval notice from the...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK0239","LU1023057109.AUD","LU1997245094.SGD","LU2097828714.EUR","LU1580142542.USD","LU2488822045.USD","LU2580892789.USD","LU1064130708.USD","BK0196","BK0183","LU2543165471.USD","01276","LU0359202008.SGD","LU0359201885.HKD","LU2097828805.USD","LU2495084118.USD","LU1064131003.USD","LU1328615791.USD","LU1655091616.SGD","LU1969619763.USD","600276","BK0060","LU2148510915.USD","LU1997245177.USD","BK0028","LU2580892862.HKD","LU1997244956.HKD","LU1255011170.USD","LU0405327148.USD","LU2097828474.EUR","LU0405327494.USD","BK0012","LU1820825898.SGD","LU0359201612.USD","LU2289578879.USD","LU1781817850.SGD","LU2097828557.USD","LU1146622755.USD","LU2097828631.EUR","LU2328871848.SGD","BK0188"],"gpt_icon":0},{"id":"1160806408","title":"Hengrui Pharma's Innovative Drug Hetrombopag Olamine Tablets Gain Additional Indication","url":"https://stock-news.laohu8.com/highlight/detail?id=1160806408","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1160806408?lang=en_us&edition=fundamental","pubTime":"2026-03-13 17:46","pubTimestamp":1773395182,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (600276.SH) has announced receiving approval from the National Medical Products Administration for an additional indication of its self-developed Class 1...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828805.USD","BK0028","LU0359201612.USD","LU1781817850.SGD","LU0359202008.SGD","LU2097828714.EUR","LU1580142542.USD","LU2148510915.USD","LU2097828557.USD","LU1997244956.HKD","BK0196","159992","LU1255011170.USD","LU2543165471.USD","BK0060","01276","LU0405327148.USD","06978","BK1574","LU1969619763.USD","LU1820825898.SGD","BK0188","LU1064131003.USD","LU2580892789.USD","LU1064130708.USD","LU2097828474.EUR","BK0183","LU2328871848.SGD","LU1328615791.USD","LU2289578879.USD","LU1023057109.AUD","600276","LU2097828631.EUR","LU0359201885.HKD","BK0239","LU1146622755.USD","BK0012","LU1655091616.SGD","LU1997245094.SGD","LU0405327494.USD","LU2580892862.HKD","BK1161","BK1191","LU1997245177.USD","LU2495084118.USD","LU2488822045.USD"],"gpt_icon":0},{"id":"2618390072","title":"Hengrui Pharmaceuticals Gets Nod to Trial SHR-9803 for Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=2618390072","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618390072?lang=en_us&edition=fundamental","pubTime":"2026-03-12 14:25","pubTimestamp":1773296740,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals  obtained approval from China's National Medical Products Administration for the clinical trial of SHR-9803 for injection, according to a Shanghai bourse filing on Thursday.The drug will be tested in combination with Adebrelimab, Bevacizumab and chemotherapy in patients with advanced malignant solid tumors.The pharmaceutical company's Hong Kong shares slipped over 1% during the afternoon trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2543165471.USD","LU0359201885.HKD","LU1023057109.AUD","01276","BK1191","LU0359201612.USD","LU0359202008.SGD"],"gpt_icon":1},{"id":"1190125604","title":"HENGRUI PHARMA (01276) Sets 25 March 2026 Board Meeting to Approve FY 2025 Results and Final Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=1190125604","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190125604?lang=en_us&edition=fundamental","pubTime":"2026-03-11 16:43","pubTimestamp":1773218617,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals Co., Ltd. (HENGRUI PHARMA, 01276) has scheduled a board meeting for Wednesday, 25 March 2026 in Shanghai. The agenda includes: 1. Reviewing and approving the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01276"],"gpt_icon":0},{"id":"2618387559","title":"Hengrui Medicine Gets Nod for Chronic Kidney Disease Drug Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2618387559","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618387559?lang=en_us&edition=fundamental","pubTime":"2026-03-10 16:58","pubTimestamp":1773133102,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Pharmaceuticals  unit Fujian Shengdi Pharmaceutical obtained the approval of China's drug administrator to start clinical trials for HRS9531 injection to treat chronic kidney disease.HRS9531 is a novel dual agonist that activates both GIP and GLP-1 receptors, which helps regulate metabolism and improve insulin sensitivity, according to a Tuesday filing with the Shanghai bourse.Shares of the pharmaceutical company closed 3% higher Tuesday.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["01276","LU1023057109.AUD","LU0359201885.HKD","LU2543165471.USD","BK1191","LU0359201612.USD","LU0359202008.SGD"],"gpt_icon":0},{"id":"2618842889","title":"China Stocks Rise on Hopes for End to Middle East Crisis; CATL Jumps 5% on Higher Profit","url":"https://stock-news.laohu8.com/highlight/detail?id=2618842889","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618842889?lang=en_us&edition=fundamental","pubTime":"2026-03-10 15:26","pubTimestamp":1773127618,"startTime":"0","endTime":"0","summary":"Hopes for an end to the war between the U.S. and Iran, as well as a better trading surplus back home, have driven Chinese stocks to rebound on Tuesday.The Shanghai Composite Index, the main gauge of C","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"327a0fad40b549b89f6d47b53d79be23","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0302445910.USD","LU2348773727.SGD","LU2298322129.HKD","LU0611395673.USD","LU0011963245.USD","LU0543330483.HKD","BK0188","LU0106259558.USD","LU1251922891.USD","LU0231483743.USD","IE00B8L5B284.USD","LU2348774022.SGD","LU1993786604.SGD","LU0164865239.USD","IE0003795394.USD","LU0244354667.USD","BK1116","LU1720050803.USD","LU1008478684.HKD","LU0469268626.HKD","LU0370786039.SGD","LU0463099449.HKD","LU0269904917.USD","SG9999003461.SGD","LU0054450605.USD","LU2298064838.USD","LU0072913022.USD","LU2153591404.USD","LU0106959298.USD","LU0051755006.USD","LU0509642566.USD","LU0607220059.USD","LU1769817179.HKD","LU0047713382.USD","LU1328615791.USD","BK0239","LU0651947912.USD","LU2476274720.SGD","LU0143863198.USD","BK0224","LU0328353924.USD","LU2097828474.EUR","LU2242644610.SGD","IE0003851619.USD","LU0828238088.HKD","SGXZ81163826.USD","LU1580142542.USD","BK1610","LU1997245094.SGD","IE00BD6J9T35.USD","LU2275660780.HKD","BK0060","LU2097828557.USD","LU2424517915.HKD","LU0254981946.USD","LU0149534421.HKD","LU0164872284.USD","LU0823414551.USD","LU1039395188.USD","LU1188198961.HKD","LU2097828805.USD","LU1997245177.USD","LU1303224171.USD","LU1721428347.USD","SG9999000459.SGD","LU1655091616.SGD","LU0516422366.SGD","LU0326950275.SGD","LU0327786744.USD","LU0505663152.USD","LU1102505762.USD","LU1868837565.USD","BK0012","LU0516422952.EUR","LU0594300419.USD","LU1934453819.USD","SG9999000327.SGD","SG9999002463.SGD","LU0405327494.USD","LU1064130708.USD","LU2039709279.SGD","LU3063872942.SGD","IE0032431581.USD","SG9999001903.USD","SG9999001689.USD","IE00B3M56506.USD","LU1719994722.HKD","LU0072462343.USD","LU0143863784.USD","LU0048575426.USD","LU1048596156.SGD","LU0405327148.USD","LU0312595415.SGD","LU0572944931.SGD","LU0651946864.USD","LU0672654166.SGD","LU2580892789.USD","LU1960683339.HKD","LU0261950470.USD","LU2148510915.USD","LU0871576103.HKD","LU1146622755.USD","LU1939255532.USD","LU0251143458.SGD","LU2153592121.USD","LU0048388663.USD","LU0880133367.SGD","LU1770034418.SGD","LU0449515922.USD","LU0594300179.USD","LU1807302812.USD","HK0000181138.USD","LU1861219969.SGD","LU2294711713.HKD","LU2449936058.SGD","LU1978683503.SGD","LU1152091754.HKD","LU2506951792.HKD","LU2778985437.USD","LU0502904849.HKD","BK0183","LU2357125470.USD","LU1023057109.AUD","LU2506952410.USD","LU0124384867.USD","LU1064131003.USD","LU2238339852.HKD","LU0823437842.USD","SGXZ49509284.SGD","LU1861214812.USD","LU1328277881.USD","LU1880383366.USD","LU0106252389.USD","LU0043850808.USD","LU0516422440.USD","LU0823426308.USD","LU0210526637.USD","LU0228659784.USD","LU0456827905.SGD","LU2495084118.USD","LU2328871848.SGD","LU0348805143.USD","LU0214875030.USD","LU0724618433.USD","LU2360107325.USD","LU2399975544.HKD","LU2506952253.HKD","LU0516423174.USD","LU0359202008.SGD","LU0049853897.USD","LU1808992512.USD","LU0326948709.USD","LU0188438112.USD","LU2097828714.EUR","LU1794554557.SGD","LU0039217434.USD","LU0823426480.USD","SG9999002828.SGD","LU1048588211.SGD","LU0181495838.USD","LU1152091168.USD","LU1969619763.USD","LU1769817096.USD","LU1242518857.USD","IE00BPRC5H50.USD","LU0455707207.USD","LU0132412106.USD","LU1242518931.SGD","SG9999001846.SGD","LU0067412154.USD","LU2488822045.USD","300750","LU2477742899.HKD","LU2249611893.SGD","LU0259732245.USD","LU0107464264.USD","LU2580892862.HKD","01276","LU0605514214.HKD","LU0650527681.SGD","LU0979878070.USD","EVS.SI","LU2506952337.HKD","LU1868838027.USD","LU0516423091.SGD","LU1820825898.SGD","IE00B543WZ88.USD","LU0140636845.USD","LU0593848301.USD","LU0192582467.USD","LU1051768304.USD","LU0828237510.HKD","600276","IE00B5MMRT66.SGD","LU1831875114.USD","LU0823414478.USD","LU0128522157.USD","LU1102505929.USD","HK0000181112.HKD","BK0196","LU0029875118.USD","LU2152927971.USD","LU0359201612.USD","LU1880383440.USD","LU0531971595.HKD","LU1997244956.HKD","LU1515016050.SGD","IE00BZ199S13.USD","LU1813983027.USD","LU0320764755.SGD","LU1961090484.USD","LU2097828631.EUR","LU0359201885.HKD","LU2476274308.USD","LU0449509016.USD","LU1781817850.SGD","LU0048580855.USD","LU0165289439.USD","LU0531970944.HKD","BK0028","LU0314109678.HKD","LU1255011170.USD","03750","IE00B8HQ1Z84.USD","LU1979443071.USD","LU0828237940.HKD","LU1051769294.HKD","LU0821914370.USD","LU0501845795.SGD","LU2289578879.USD"],"gpt_icon":1},{"id":"2618643934","title":"Jiangsu Hengrui Pharmaceuticals Gets China Nod for Two Anti-Tumor Injectables","url":"https://stock-news.laohu8.com/highlight/detail?id=2618643934","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618643934?lang=en_us&edition=fundamental","pubTime":"2026-03-09 15:40","pubTimestamp":1773042048,"startTime":"0","endTime":"0","summary":"China's drug regulator obtained approval for the adebelimab and the SHR-8068 injections produced by Jiangsu Hengrui Pharmaceuticals  subsidiaries Suzhou Shengdiya Biomedical and Shanghai Shengdi Pharmaceutical.The two injections are indicated for tumor treatments, according to a Saturday filing with the Shanghai bourse.Shares closed 1% lower in Shanghai on Monday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2543165471.USD","LU0359201612.USD","01276","BK1191","LU0359202008.SGD","LU1023057109.AUD","LU0359201885.HKD"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}